SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Henry Brian)
 

Sökning: WFRF:(Henry Brian) > The Impact of Empag...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003867naa a2200409 4500
001oai:gup.ub.gu.se/299707
003SwePub
008240528s2020 | |||||||||||000 ||eng|
0247 a https://gup.ub.gu.se/publication/2997072 URI
0247 a https://doi.org/10.2337/dc20-10962 DOI
040 a (SwePub)gu
041 a eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Neeland, Ian J4 aut
2451 0a The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial.
264 c 2020-10-01
264 1b American Diabetes Association,c 2020
520 a To explore the effects of empagliflozin on the incidence of obstructive sleep apnea (OSA) and its effects on metabolic, cardiovascular (CV), and renal outcomes among participants with or without OSA in the EMPA-REG OUTCOME trial.Participants with diabetes and CV disease were randomized to empagliflozin (10 and 25 mg) or placebo daily in addition to standard of care. OSA was assessed by investigator report using Medical Dictionary for Regulatory Activities version 18.0, and CV outcomes were independently adjudicated. Analyses were performed using multivariable-adjusted Cox regression models.OSA was reported in 391 of 7,020 (5.6%) participants at baseline. Those with OSA were more likely to be male (83% vs. 71%) and to have moderate to severe obesity (BMI ≥35 kg/m2; 55% vs. 18%). Over a median of 3.1 years, empagliflozin had similar placebo-adjusted reductions in HbA1c, waist circumference, and systolic blood pressure, regardless of OSA status, but a larger effect on weight (adjusted mean ± SE difference at week 52: OSA vs. no OSA -2.9 ± 0.5 vs. -1.9 ± 0.1 kg). Incidence of 3-point major adverse CV events, CV death, heart failure hospitalization, and incident or worsening nephropathy in the placebo group was 1.2- to 2.0-fold higher for those with baseline OSA compared with those without. Empagliflozin significantly reduced the risk for outcomes regardless of OSA status (P-interaction all >0.05). Fifty patients reported a new diagnosis of OSA through 7 days after medication discontinuation, and this occurred less often with empagliflozin treatment (hazard ratio 0.48 [95% CI 0.27, 0.83]).In EMPA-REG OUTCOME, participants with OSA had greater comorbidity and higher frequency of CV and renal events. Empagliflozin had favorable effects on risk factors and CV and renal outcomes regardless of preexisting OSA and may also reduce the risk for new-onset OSA.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Endokrinologi och diabetes0 (SwePub)302052 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Endocrinology and Diabetes0 (SwePub)302052 hsv//eng
7001 a Eliasson, Björn,d 1959u Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine4 aut0 (Swepub:gu)xelibj
7001 a Kasai, Takatoshi4 aut
7001 a Marx, Nikolaus4 aut
7001 a Zinman, Bernard4 aut
7001 a Inzucchi, Silvio E4 aut
7001 a Wanner, Christoph4 aut
7001 a Zwiener, Isabella4 aut
7001 a Wojeck, Brian S4 aut
7001 a Yaggi, Henry K4 aut
7001 a Johansen, Odd Erik4 aut
7102 a Göteborgs universitetb Institutionen för medicin, avdelningen för molekylär och klinisk medicin4 org
7730 t Diabetes Cared : American Diabetes Associationg 43:12, s. 3007-3015q 43:12<3007-3015x 1935-5548x 1935-5548x 0149-5992
8564 u https://diabetesjournals.org/care/article-pdf/43/12/3007/530820/dc201096.pdf
8564 8u https://gup.ub.gu.se/publication/299707
8564 8u https://doi.org/10.2337/dc20-1096

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy